RIM
ALXN

Ranger Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Ranger Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-103
Closed -$20K – 152
2015
Q4 		$20K Hold
103
– – ﹤0.01% 113
2015
Q3 		$16K Hold
103
– – ﹤0.01% 115
2015
Q2 		$19K Buy
103
+51
+98% +$8.8K ﹤0.01% 123
2015
Q1 		$9K Sell
52
-4,358
-99% -$789K ﹤0.01% 119
2014
Q4 		$816K Hold
4,410
– – 0.04% 96
2014
Q3 		$731K Buy
+4,410
New +$724K 0.04% 88

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ranger Investment Management's ALXN Position: Q1 2016 in Review

Ranger Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2016, closing a stake of 103 shares — an estimated $20K sold.

Ranger Investment Management first reported a position in ALXN in Q3 2014 and held it in 6 quarters. The position peaked at $816K in Q4 2014. 519 funds tracked by Wall St. Rank hold ALXN as of Q1 2016.

  • Ranger Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Ranger Investment Management sold 103 Alexion Pharmaceuticals shares in Q1 2016, an estimated $20K.
  • Ranger Investment Management first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 6 quarters.
  • Ranger Investment Management's Alexion Pharmaceuticals position peaked at $816K in Q4 2014.
  • 519 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2016.

Based on Ranger Investment Management's 13F filing for Q1 2016, filed 16 May 2016.